TY  - JOUR
AU  - Miederer, Matthias
AU  - Benešová-Schäfer, Martina
AU  - Mamat, Constantin
AU  - Kästner, David
AU  - Pretze, Marc
AU  - Michler, Enrico
AU  - Brogsitter, Claudia
AU  - Kotzerke, Jörg
AU  - Kopka, Klaus
AU  - Scheinberg, David A
AU  - McDevitt, Michael R
TI  - Alpha-Emitting Radionuclides: Current Status and Future Perspectives.
JO  - Pharmaceuticals
VL  - 17
IS  - 1
SN  - 1424-8247
CY  - Basel
PB  - MDPI
M1  - DKFZ-2024-00190
SP  - 76
PY  - 2024
AB  - The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.
KW  - actinium-225 (Other)
KW  - alpha emitter (Other)
KW  - high let (Other)
KW  - targeted alpha therapy (Other)
KW  - theranostic (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38256909
DO  - DOI:10.3390/ph17010076
UR  - https://inrepo02.dkfz.de/record/287258
ER  -